HER2 in resected gastric cancer: Is there prognostic value?

Fisher, Sarah B.; Fisher, Kevin E.; Squires, Malcolm H.; Patel, Sameer H.; Kooby, David A.; El‐Rayes, Bassel F.; Cardona, Kenneth; Russell, Maria C.; Staley, Charles A.; Farris, Alton B.; Maithel, Shishir K.

doi:10.1002/jso.23456

Cited by 30 publications

(23 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although some studies have reported that HER2 positivity is a poor prognostic factor in gastric cancer [8][9][10][11], others have found that HER2 has no influence on prognosis [12][13][14][15].…”

Section: Discussionmentioning

confidence: 99%

“…In contrast to breast cancer in which HER2 is known as a poor prognostic factor [7], the prognostic value of HER2 in gastric cancer is still controversial. Even though some studies have shown that HER2-positivity in gastric cancer is associated with poor outcomes and less sensitive to cytotoxic chemotherapy [8][9][10][11], others have demonstrated that HER2 expression does not influence overall prognosis in gastric cancer [12][13][14][15]. Moreover, it has been getting harder to determine the prognostic value of HER2 per se in AGC after routine prescription of trastuzumab for HER2-positive patients, which can significantly prolong OS [6].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications

et al. 2015

View full text Add to dashboard Cite

Background In advanced gastric cancer (AGC), HER2 is a validated therapeutic target. However, the metabolic landscape of AGC based on HER2 status has not been reported. Furthermore, the prognostic value of HER2 in AGC is under debate. The purpose of this study was to determine the metabolic landscape and prognosis on the basis of HER2 status in AGC. Methods We analyzed 866 AGC patients treated with palliative chemotherapy and whose HER2 status was evaluated. HER2 positivity was defined as HER2 IHC 3? or HER2/CEP17 ratio C2. Among them, 363 patients were evaluated with 18 F FDG-PET before chemotherapy. We analyzed mSUV (maximal standardized uptake value) according to HER2 status and clinical outcomes. Results Among 866 patients, 225 (26.0 %) had HER2? GC. The mSUV of HER2? GC was significantly higher than that of HER2-GC (12.6 vs. 8.7, p \ 0.001). Increased HER2 IHC positivity was correlated with increased mSUV

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The HER2 overexpression is more frequently observed in gastroesophageal junction tumours than in those with distal gastric location and it is more often associated with the intestinal type adenocarcinomas [83–90]. Cancers positive for HER2 overexpression are usually differentiated tumours [43, 80, 91]. ERBB2 gene mutation that leads to HER2 overexpression occurs in the early stage of carcinogenesis [92].…”

Section: Her2mentioning

confidence: 99%

Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer

Carlomagno

Incollingo

Tammaro

et al. 2017

BioMed Research International

View full text Add to dashboard Cite

Introduction Gastric cancer is the fifth most common cancer and the third cause of cancer death. The clinical outcomes of the patients are still not encouraging with a low rate of 5 years' survival. Often the disease is diagnosed at advanced stages and this obviously negatively affects patients outcomes. A deep understanding of molecular basis of gastric cancer can lead to the identification of diagnostic, predictive, prognostic, and therapeutic biomarkers. Main Body This paper aims to give a global view on the molecular classification and mechanisms involved in the development of the tumour and on the biomarkers for gastric cancer. We discuss the role of E-cadherin, HER2, fibroblast growth factor receptor (FGFR), MET, human epidermal growth factor receptor (EGFR), hepatocyte growth factor receptor (HGFR), mammalian target of rapamycin (mTOR), microsatellite instability (MSI), PD-L1, and TP53. We have also considered in this manuscript new emerging biomarkers as matrix metalloproteases (MMPs), microRNAs, and long noncoding RNAs (lncRNAs). Conclusions Identifying and validating diagnostic, prognostic, predictive, and therapeutic biomarkers will have a huge impact on patients outcomes as they will allow early detection of tumours and also guide the choice of a targeted therapy based on specific molecular features of the cancer.

show abstract

“…Although the role of HER-2 in this tumor has already been extensively investigated [19], and found to be frequently associated with invasion, high grade, and unfavorable prognosis, its overall prognostic role remains controversial [20-24] and appears to be stage-dependent.…”

Section: Her-2 As a Key Target In Gastric Cancers And Gastroesophageamentioning

confidence: 99%

HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives

et al. 2016

View full text Add to dashboard Cite

HER-2 (ErbB-2, c-erbB2 or Her2/neu), a member of the HER-family, is directly involved in the pathogenesis and progression of several human cancers; as such, it is also often considered as a poor prognostic factor. Following the revolutionary impact of anti-HER-2 therapy in breast cancer patients, the role of HER-2 and its blockade has also been extensively evaluated in other tumor types, including gastric and colorectal adenocarcinoma. The aims of this review are to recall the important results achieved with the use of HER-2 inhibitors in both gastric and colorectal cancer, and to discuss on the updates available on the role of HER-2 as prognostic and predictive factor in these malignancies.

show abstract

HER2 in resected gastric cancer: Is there prognostic value?

Abstract: HER2 amplification/over-expression is present in patients with resected gastric adenocarcinoma, but is not associated with the presence of adverse prognostic factors. Our results suggest HER2 is not prognostic for patients with resected gastric adenocarcinoma.

Cited by 30 publications

References 31 publications

Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications

Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications

Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer

HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives

Contact Info

Product

Resources

About